← ANALYST RATINGS · TIPRANKS
Elicio Therapeutics (ELTX): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy1 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $15.50, the highest $23.00, the lowest $8.00. The average is +893.6% from the last price of $1.56.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $1.50−25.0% | Hold | −3.8% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $1.50−25.0% | Hold | −3.8% | Reiterated | 01.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Hold | −3.8% | Reiterated | 01.10.26on TipRanks 04:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 | Hold | +28.2% | Reiterated | 30.09.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 | Sell | −3.8% | Downgrade | 30.09.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.50 | Sell | −3.8% | Downgrade | 30.09.26on TipRanks 03:05 | — | |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $27.00 → $8.00−70.4% | Buy | +412.8% | Reiterated | 24.09.26on TipRanks 08:40 | +0.6%next day −2.7% · 5 days +2.5% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $23.00 | Buy | +1,374.4% | Reiterated | 21.08.26on TipRanks Aug 18 06:25 | +3.7%next day +0.4% · 5 days −3.0% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | — | Hold | — | Reiterated | 17.08.26on TipRanks 07:57 | −1.8%next day +3.7% · 5 days −0.1% | ↗ |
| Kevin DeGeeter★★★★★★★★★★#705 · hits 38% · avg +19.0% | Ladenburg Thalmann & Co. | $12.00 | Buy | +669.2% | Initiated | 18.06.26on TipRanks 09:10 | −19.3%next day +7.8% · 5 days +6.3% | ↗ |
| Michael King★★★★★★★★★★#11053 · hits 39% · avg −2.3% | Rodman & Renshaw | $17.00 | Buy | +989.7% | Initiated | 09.03.26on TipRanks 16:25 | +9.7%next day −8.5% · 5 days −4.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Elicio Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.50 at a price of $1.82 (+751.6%); now: $15.50 at $1.56 (+893.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 9 | 6 | 5 | 2 | 2 |
| Buy | 2 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 2 | 2 | 3 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Elicio Therapeutics
- CEO: Robert T. Connelly
- Employees: 33
- 451 D Street, Boston, MA, 02210, US
- elicio.com
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 51 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗